Notice: This company has been marked as potentially delisted and may not be actively trading. Albireo Pharma (ALBO) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Albireo Launches Critical Alarm Management Service for Mission Critical Buildings that Require Uptime and ReliabilityMay 6, 2024 | businesswire.comProspect Park II in Fort LauderdaleJanuary 19, 2024 | bizjournals.comALBO Historical DataOctober 1, 2023 | investing.comAlbireo Pharma (NASDAQ:ALBO) Coverage Initiated by Analysts at StockNews.comStockNews.com started coverage on shares of Albireo Pharma in a research report on Thursday. They issued a "sell" rating for the company.March 30, 2023 | marketbeat.comAlbireo Pharma, Inc. (NASDAQ:ALBO) Receives Consensus Rating of "Hold" from AnalystsAlbireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) has been given an average rating of "Hold" by the eight brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy ratMarch 27, 2023 | marketbeat.comStockNews.com Begins Coverage on Albireo Pharma (NASDAQ:ALBO)StockNews.com started coverage on shares of Albireo Pharma in a research note on Tuesday. They set a "sell" rating on the stock.March 14, 2023 | marketbeat.comIpsen Pharma: Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolioMarch 4, 2023 | finanznachrichten.deFederated Hermes Inc. Has $43.72 Million Position in Albireo Pharma, Inc. (NASDAQ:ALBO)Federated Hermes Inc. increased its position in Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) by 0.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,258,124 shares of the biopharmaceutical company's stock after buying an additional 3,000 sharMarch 3, 2023 | marketbeat.comShort Interest in Albireo Pharma, Inc. (NASDAQ:ALBO) Declines By 19.8%Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 553,900 shares, a drop of 19.8% from the January 31st total of 690,300 shares. Based on an average daily trading volume, of 445,800 shares, the short-interest ratio is currently 1.2 days.March 3, 2023 | marketbeat.comTower Research Capital LLC TRC Boosts Stock Holdings in Albireo Pharma, Inc. (NASDAQ:ALBO)Tower Research Capital LLC TRC boosted its position in shares of Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) by 560.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,732 shares of theMarch 1, 2023 | marketbeat.comAlbireo Pharma, Inc. (NASDAQ:ALBO) Stock Position Trimmed by ExodusPoint Capital Management LPExodusPoint Capital Management LP decreased its position in Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) by 32.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 35,874 shares of the biopharmaceutical company's stFebruary 27, 2023 | marketbeat.comALBO Albireo Pharma, Inc.February 25, 2023 | seekingalpha.comConnor Clark & Lunn Investment Management Ltd. Acquires New Shares in Albireo Pharma, Inc. (NASDAQ:ALBO)Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 10,061 shares of the biopharmaceutical company'sFebruary 24, 2023 | marketbeat.comAlbireo Pharma, Inc. (ALBO)February 18, 2023 | uk.finance.yahoo.comPrudential Financial Inc. Sells 41,800 Shares of Albireo Pharma, Inc. (NASDAQ:ALBO)Prudential Financial Inc. lowered its position in shares of Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) by 61.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,700 shares of the biopharmaceutical company's stock after selling 41,February 16, 2023 | marketbeat.comAlbireo Gets FDA Priority Review of Bylvay in Alagille Syndrome >ALBOFebruary 14, 2023 | marketwatch.comFDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeFebruary 14, 2023 | finance.yahoo.comDekaBank Deutsche Girozentrale Grows Position in Albireo Pharma, Inc. (NASDAQ:ALBO)DekaBank Deutsche Girozentrale increased its position in shares of Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) by 28.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 45,000 shares of the biopharmaceutical comJanuary 27, 2023 | marketbeat.comALBO.PH - | Stock Price & Latest News | ReutersJanuary 24, 2023 | reuters.comWhy These Two Biotech Stocks Blasted Higher This WeekJanuary 21, 2023 | finance.yahoo.comHC Wainwright Weighs in on Albireo Pharma, Inc.'s FY2027 Earnings (NASDAQ:ALBO)Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) - HC Wainwright issued their FY2027 earnings estimates for Albireo Pharma in a research report issued to clients and investors on Tuesday, January 10th. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will earn $19.05 per shJanuary 13, 2023 | marketbeat.comCowen & Co. Downgrades Albireo Pharma: Here's What You Need To KnowJanuary 11, 2023 | msn.comAnalysts move to downgrade Albireo Pharma after Ipsen's proposed acquisitionJanuary 11, 2023 | msn.comAlbireo Pharma Spikes On Agreement To Be Acquired By IpsenJanuary 11, 2023 | nasdaq.comExpert Ratings for Albireo PharmaJanuary 11, 2023 | markets.businessinsider.comAlbireo Pharma (NASDAQ:ALBO) Rating Lowered to Neutral at GuggenheimGuggenheim downgraded Albireo Pharma from a "buy" rating to a "neutral" rating in a report on Wednesday.January 11, 2023 | marketbeat.comEquities Analysts Issue Forecasts for Albireo Pharma, Inc.'s FY2027 Earnings (NASDAQ:ALBO)Albireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) - Stock analysts at Wedbush issued their FY2027 earnings per share estimates for shares of Albireo Pharma in a note issued to investors on Monday, January 9th. Wedbush analyst A. Argyrides expects that the biopharmaceutical company will post earningJanuary 10, 2023 | marketbeat.comShareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with IpsenJanuary 9, 2023 | benzinga.comALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to ShareholdersJanuary 9, 2023 | technews.tmcnet.comFrance-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, PipelineJanuary 9, 2023 | finance.yahoo.comAlbireo: Slowly Capturing Some Of The Liver Disease MarketJanuary 2, 2023 | seekingalpha.comWe're Not Very Worried About Albireo Pharma's (NASDAQ:ALBO) Cash Burn RateDecember 21, 2022 | finance.yahoo.comAlbireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of DirectorsDecember 6, 2022 | finance.yahoo.comReimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2November 30, 2022 | finance.yahoo.comFY2022 Earnings Estimate for Albireo Pharma, Inc. (NASDAQ:ALBO) Issued By William BlairAlbireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) - Stock analysts at William Blair upped their FY2022 earnings estimates for shares of Albireo Pharma in a note issued to investors on Wednesday, November 9th. William Blair analyst T. Lugo now anticipates that the biopharmaceutical company will postNovember 14, 2022 | marketbeat.comAlbireo Pharma (NASDAQ:ALBO) dips 16% this week as increasing losses might not be inspiring confidence among its investorsNovember 10, 2022 | finance.yahoo.comAlbireo to Participate in Jefferies London Healthcare ConferenceNovember 9, 2022 | finance.yahoo.comAlbireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | seekingalpha.comAlbireo Reports Q3 2022 Financial Results and Business UpdateNovember 8, 2022 | finance.yahoo.comAlbireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue EstimatesNovember 8, 2022 | finance.yahoo.comBylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC TypesNovember 7, 2022 | finance.yahoo.comAlbireo Announces 2022 SPARK Grant WinnersNovember 3, 2022 | finance.yahoo.comAlbireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary AtresiaNovember 2, 2022 | finance.yahoo.comAlbireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022November 1, 2022 | finance.yahoo.comAlbireo to Report Q3 2022 Financial Results on November 8, 2022October 31, 2022 | finance.yahoo.comAnalysts Expect Mirum Pharma's Liver Disease Candidate Might Exceed Rival Product's PenetrationOctober 25, 2022 | finance.yahoo.comInsider Selling: Albireo Pharma, Inc. (NASDAQ:ALBO) CEO Sells 919 Shares of StockAlbireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) CEO Ronald Harold Wilfred Cooper sold 919 shares of the company's stock in a transaction on Monday, October 24th. The shares were sold at an average price of $19.58, for a total value of $17,994.02. Following the completion of the transaction, the chief executive officer now owns 55,461 shares of the company's stock, valued at $1,085,926.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.October 25, 2022 | marketbeat.comAlbireo Pharma (NASDAQ:ALBO) Price Target Raised to $59.00 at GuggenheimOctober 17, 2022 | marketbeat.comAlbireo Pharma, Inc. (NASDAQ:ALBO) Short Interest Down 13.3% in SeptemberOctober 15, 2022 | marketbeat.comQ3 2022 EPS Estimates for Albireo Pharma, Inc. (NASDAQ:ALBO) Increased by AnalystAlbireo Pharma, Inc. (NASDAQ:ALBO - Get Rating) - Research analysts at Jefferies Financial Group raised their Q3 2022 EPS estimates for Albireo Pharma in a research note issued on Tuesday, October 11th. Jefferies Financial Group analyst E. Yang now anticipates that the biopharmaceutical company wOctober 14, 2022 | marketbeat.com Get Albireo Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. ALBO Media Mentions By Week ALBO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALBO News Sentiment▼0.200.47▲Average Medical News Sentiment ALBO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALBO Articles This Week▼00▲ALBO Articles Average Week Get Albireo Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies COLL News ANAB News VNDA News GOSS News RYTM News APLS News PTCT News MLTX News VRNA News HCM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALBO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Albireo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Albireo Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
